V7B Stock Overview
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Assembly Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.40 |
| 52 Week High | US$14.45 |
| 52 Week Low | US$7.51 |
| Beta | 0.61 |
| 1 Month Change | 5.30% |
| 3 Month Change | 30.64% |
| 1 Year Change | 13.30% |
| 3 Year Change | -72.07% |
| 5 Year Change | -92.51% |
| Change since IPO | -82.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| V7B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.7% | -3.1% | 1.8% |
| 1Y | 13.3% | -22.4% | 2.2% |
Return vs Industry: V7B exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: V7B exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| V7B volatility | |
|---|---|
| V7B Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V7B's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine V7B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 65 | Jason Okazaki | www.assemblybio.com |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States. It develops ABI-5366 and ABI-1179, which is in Phase 1a/1b clinical trial targeting recurrent genital herpes; and ABI-6250, an oral hepatitis delta virus entry inhibitor that is in Phase 1a clinical studies. The company also offers ABI-4334, a next-generation capsid assembly modulator which is in Phase 1b clinical trials, for the treatment of hepatitis B virus.
Assembly Biosciences, Inc. Fundamentals Summary
| V7B fundamental statistics | |
|---|---|
| Market cap | €68.09m |
| Earnings (TTM) | -€57.30m |
| Revenue (TTM) | €6.70m |
10.3x
P/S Ratio-1.2x
P/E RatioIs V7B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V7B income statement (TTM) | |
|---|---|
| Revenue | US$7.16m |
| Cost of Revenue | US$2.12m |
| Gross Profit | US$5.05m |
| Other Expenses | US$66.28m |
| Earnings | -US$61.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.17 |
| Gross Margin | 70.46% |
| Net Profit Margin | -854.78% |
| Debt/Equity Ratio | 0% |
How did V7B perform over the long term?
See historical performance and comparison